Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533169 · ClinicalTrials.gov registry record · Phase 1
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00533169: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00533169 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00533169, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of the drug ZactimaTM (ZD6474) in patients with neuroblastoma or medulloblastoma that has gotten worse, has come back, or has not responded to the treatment. Primary Objective: -To determine the pharmacokinetics, safety, dose-limiting toxicities, and maximum tolerated dose of ZD6474, alone in children with medulloblastoma, and alone in combination with retinoic acid, in patients with relapsed or refractory neuroblastoma. Secondary Objective: -To assess progression-free survival (PFS) and objective tumor response rates in children with relapsed and refractory neuroblastoma and medulloblastoma treated with ZD6474 +/- retinoic acid in the context of a Phase I trial.
Interventions
- DRUG ZD6474
- DRUG Retinoic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533169
The ClinicalTrials.gov registry entry for NCT00533169 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ZD6474 is the first listed.
NCT00533169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533169 about?
NCT00533169 is a clinical study titled "ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma". The goal of this clinical research study is to find the highest safe dose of the drug ZactimaTM (ZD6474) in patients with neuroblastoma or medulloblastoma that has gotten worse, has come back, or has not responded to the treatment. Primary Objective: -To determine the pharmacokinetics, safety, dos...
What is the current status of trial NCT00533169?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-09. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00533169?
The interventions under investigation include: ZD6474 (DRUG), Retinoic Acid (DRUG).
Who is sponsoring clinical trial NCT00533169?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.